East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Etodolac Tablets USP, 400 mg and 500 mg. Aurobindo Pharma’s Etodolac Tablets USP, are an AB-rated generic equivalent to the reference listed drug (RLD), Lodine® Tablets, manufactured by Wyeth Pharmaceuticals Inc.

Etodolac Tablets are indicated:

• For acute and long-term use in the management of signs and symptoms of the following:
  1. Osteoarthritis
  2. Rheumatoid arthritis
• For the management of acute pain.